REDWOOD CITY, Calif., Feb. 24, 2016 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that the company's President and Chief Executive Officer Peter Van Vlasselaer, Ph.D. will present at the following upcoming investor conference:
Event: Cowen and Company 36th Annual Heath Care Conference
Date: Wednesday, March 9, 2016
Time: 9:00 - 9:25 am Eastern Time (6:00 – 6:25 am Pacific Time)
Location: The Boston Marriott Copley Place, Boston, MA
About ARMO BioSciences:
Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company's lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. ARMO plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors. The company also has a robust pipeline of therapeutic cytokines and an anti-PD-1 checkpoint inhibitor.
For more information, please visit www.armobio.com
Scott Ogg, Ph.D.
Vice President Corporate Development and Operations
SOURCE ARMO BioSciences, Inc.